SCHEMBL9944210

SCHEMBL9944210

CC(=O)c1ccc(NC(=O)c2cc(F)c(OC(C)C)c(Cl)c2)cc1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 2/20 0.47
KCNQ3 O43525 3/20 0.47
KCNQ2 O43526 3/20 0.47
TAS1R3 Q7RTX0 2/20 0.44
TAS1R1 Q7RTX1 2/20 0.44
TAS1R2 Q8TE23 2/20 0.44
KCNE1 P15382 2/20 0.43
KCNQ1 P51787 2/20 0.43
RORC P51449 1/20 0.43
NPC1 O15118 7/20 0.42
RAB9A P51151 7/20 0.42
POLB P06746 1/20 0.42
CASP3 P42574 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
KCNQ5 Q9NR82 1/20 0.42
MAPT P10636 3/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1458621 0.92 PLAU (0.47) PLAUKCNQ3KCNQ2TAS1R3TAS1R1
SCHEMBL9944164 0.92 PLAU (0.49) PLAUTAS1R3TAS1R1TAS1R2RORC
SCHEMBL9944173 0.90 RORC (0.48) PLAUTAS1R3TAS1R1TAS1R2RORC
SCHEMBL9944193 0.88 RORC (0.49) PLAUKCNQ3KCNQ2TAS1R3TAS1R1
SCHEMBL9944205 0.87 PLAU (0.47) PLAUKCNQ3KCNQ2TAS1R3TAS1R1
SCHEMBL9944076 0.84 RAB9A (0.50) PLAUTAS1R3TAS1R1TAS1R2RORC
SCHEMBL9944209 0.83 TAS1R3 (0.52) PLAUTAS1R3TAS1R1TAS1R2RORC
SCHEMBL9944221 0.83 MAPT (0.54) PLAURORCNPC1RAB9APOLB
SCHEMBL9944230 0.82 RORC (0.48) PLAUKCNQ3KCNQ2TAS1R3TAS1R1
SCHEMBL9944199 0.82 TAS1R3 (0.65) TAS1R3TAS1R1TAS1R2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9447028-B2 Therapeutic aryl-amido-aryl compounds and their use KING'S COLLEGE LONDON (GB) 2016-09-20 US disclosed
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2016-02-11 US disclosed
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG PLAU 4014/4885KCNQ3 4487/4885KCNQ2 4326/4885
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG PLAU 4014/4885KCNQ3 4487/4885KCNQ2 4326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.